Fate Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf cellular immunotherapy products by engineering human induced pluripotent stem cells (iPSCs) into standardized T-cell and NK-cell therapies through its proprietary "cellular programming" platform. The company manufactures clonal master iPSC lines that serve as renewable sources for mass-produced, uniform therapies that can be stored and administered on-demand, addressing the logistical complexity, cost, and manufacturing variability limitations of current autologous cell therapies. Its pipeline targets autoimmune diseases and hematologic and solid tumors, with lead programs in clinical development; the company generates revenue through strategic partnerships and development collaborations that provide R&D funding, milestone payments, and royalties, while building toward independent or partnered commercialization once products achieve regulatory approval.